NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells.
Neurotech Pharmaceuticals Inc is developing NT-501, an implantable polymeric device containing a genetically modified cell line that secretes ciliary neurotrophic factor, for the potential treatment of retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Phase III clinical trials for RP and a phase II clinical trial for dry AMD are ongoing. A phase I clinical trial showed that NT-501 treatment was well tolerated with variable, but positive improvements in visual acuity.
Emerich
Dwaine F
DF
InCytu Inc, Lincoln, RI 02865, USA. emerich@incytu.com
Thanos
Christopher G
CG
D002460:Cell Line / Q000378:metabolism* / Q000637:transplantation*; D018914:Cells, Immobilized / Q000637:transplantation*; D020934:Ciliary Neurotrophic Factor / Q000096:biosynthesis* / Q000235:genetics; D002986:Clinical Trials as Topic; D006801:Humans; D008268:Macular Degeneration / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D011108:Polymers; D019736:Prostheses and Implants; D012174:Retinitis Pigmentosa / Q000235:genetics / Q000378:metabolism / Q000628:therapy*
D020934:Ciliary Neurotrophic Factor; D011108:Polymers